Suggestions
Rinol Alaj
Senior Director, Head of Clinical Outcomes Assessment & Patient Innovation at Regeneron Pharmaceuticals, Inc.
Rinol Alaj is a senior executive at Regeneron Pharmaceuticals, currently serving as the Senior Director, Head of Clinical Outcomes Assessment & Patient Innovation.13 He has been with Regeneron since August 2017, initially joining as the Director, Head of Clinical Outcomes Assessment & Patient Innovation in Clinical Trial Management before being promoted to his current role in January 2022.3
Alaj has extensive experience in the pharmaceutical industry, having previously worked at Merck for about 7 years in various roles related to patient-reported outcomes and clinical trial technologies.3 His expertise lies in integrated innovation, design thinking, and the implementation of digital health technologies in clinical trials.3
Academically, Alaj holds multiple degrees:
- Bachelor's and Master's degrees in Computer Science from the New Jersey Institute of Technology
- MBA in Business Administration with a concentration in Management Information Systems from the New Jersey Institute of Technology
- Master of Public Health (MPH) in Epidemiology and Biostatistics from CUNY Graduate School of Public Health and Health Policy3
At Regeneron, Alaj is particularly focused on the development and implementation of digital biomarkers in clinical trials. He leads the company's Digital Biomarker Lab and chairs their annual Digital Biomarkers Summit, which brings together industry leaders to collaborate on advancing digital biomarker adoption.14 Alaj is a strong advocate for industry-wide collaboration in this field, emphasizing that companies should compete on drugs, not digital biomarkers.1
Alaj is also actively involved in industry conferences, such as DPHARM 2024, where he leads panel discussions on advancing scalability and operationalizing digital endpoints in clinical trials.1 His work aims to make clinical trials more effective, faster, and patient-centric through the use of digital technologies.12


